Hospital infection therapeutics industry forecast
Hospital-acquired infections, also known as nosocomial infections, are acquired by patients in the hospitals or healthcare facilities. Urinary tract infections, bloodstream infections, surgical-site infections, Clostridium difficile associated diarrhea, and pneumonia are examples of nosocomial infections. Based on the hospital infection therapeutics industry analysis, it is estimated that this market to surpass USD 3 billion by 2019 due to the widespread availability of treatment measures in developed nations.
The recent rise in public health awareness is the key driver for the growth of this market. As the populace is increasingly becoming aware of the infections acquired in hospital settings, the availability of treatment options is expected to augment the use of drugs to treat such diseases.
Competitive landscape and key vendors
This market is expected to grow gradually during the forecast period owing to the augmented number of infection control programs and increased awareness about the diseases. The vendors manufacturing and marketing hospital infection therapeutics that can effectively treat and cure various life-threatening diseases are expected to gain a competitive edge over their peers.
Key vendors in this market are
- Allergan
- Bayer
- GlaxoSmithKline
- Merck
- Pfizer
Other prominent vendors are Abbott Laboratories, Achaogen, AmpliPhi Biosciences, Angelini Pharma, Aridis Pharmaceuticals, AstraZeneca, Durata Therapeutics, F. Hoffmann-La Roche, Isis Pharmaceuticals, Johnson & Johnson, Ligand Pharmaceuticals, Massachusetts Biological Laboratories, Medarex, Meiji Seika Pharma, Melinta Therapeutics, Nektar, Novartis, Prokarium, Sanofi, Tetraphase Pharmaceuticals, the Medicines Company, and Valneva.
Segmentation by type of infections and analysis of the hospital infection therapeutics market
- Urinary tract infections
- Respiratory tract infections
- Bloodstream infections
- Surgical site infections
- Gastrointestinal infections
In this market research report, analysts have estimated urinary tract infections to be the most common form of nosocomial infections. This infection is common in both non-catheterized and catheterized patients and is commonly found in high-income countries. The increasing usage of combination antibiotics for the treatment of such infections is expected to drive market growth during the forecast period.
Geographical segmentation of the hospital infection therapeutics market
Technavio’s market research analyst has estimated the Americas to dominate this market during the forecast period. The availability of better healthcare facilities in this region is expected to result in its high market share of approximately 43% during the forecast period.
Key questions answered in the report include
- What will the market size and the growth rate be in 2019?
- What are the key factors driving the hospital infection therapeutics market?
- What are the key market trends impacting the growth of the hospital infection therapeutics market?
- What are the challenges to market growth?
- Who are the key vendors in the hospital infection therapeutics market?
- What are the market opportunities and threats faced by the vendors in the hospital infection therapeutics market?
- Trending factors influencing the market shares of the EMEA, Americas, and APAC?
- What are the key outcomes of the five forces analysis of the hospital infection therapeutics market?
Technavio also offers customization on reports based on specific client requirement.
Related reports